Literature DB >> 33772101

LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway.

Yifu Hou1,2, Kai Chen1,2, Rui Liao3, Youzan Li3, Hongji Yang4,5, Jun Gong6,7.   

Abstract

Hepatocellular carcinoma (HCC) is a rapidly growing tumor characterized by a high potential for vascular invasion and metastasis. The purpose of our study is to explore the regulation mechanism of long noncoding RNA (lncRNA) LINC01419 on cell-cycle distribution and metastasis in hepatocellular carcinoma (HCC) by regulating zinc finger of the cerebellum (ZIC1) through PI3K/Akt signaling pathway. Bioinformatics analysis and dual-luciferase reporter assay were used to analyze LINC01419 and related genes in HCC, and their expression in HCC tissues and adjacent normal tissues were determined by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot. Then, HCC cell lines were subjected to the construction of LINC01419/ZIC1 overexpression/knockdown cells utilizing lentiviral vectors. RIP and ChIP assays were applied to identify the LINC01419-binding protein. BSP and MSP assays were used to determine gene methylation. According to the results, LINC01419 was highly expressed in HCC tissues and cells, while ZIC1 was poorly expressed. LINC01419 targeted and downregulated ZIC1 expression. Furthermore, LINC01419 increased the methylation of ZIC1 promoter and repressed ZIC1 expression. PI3K/Akt signaling pathway was activated by LINC01419 overexpression and ZIC1 knockdown, under which conditions, the HCC cell self-renewal and proliferation were promoted while cell apoptosis was attenuated, accompanied by accelerated formation and metastasis of xenografted tumors in mice. In conclusion, LINC01419 enhances the methylation of ZIC1 promoter, inhibits ZIC1 expression, and activates the PI3K/Akt signaling pathway, thereby enhancing the malignant phenotypes of HCC cells in vitro as well as tumor formation and metastasis in vivo.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33772101     DOI: 10.1038/s41374-021-00539-z

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  37 in total

1.  Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Jelic; G C Sotiropoulos
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

Review 5.  Guide for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Magdy Hamed Attwa; Shahira Aly El-Etreby
Journal:  World J Hepatol       Date:  2015-06-28

6.  Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy.

Authors:  Sheng-Xian Yuan; Fu Yang; Yuan Yang; Qi-Fei Tao; Jin Zhang; Gang Huang; Yun Yang; Ruo-Yu Wang; Sen Yang; Xi-Song Huo; Ling Zhang; Fang Wang; Shu-Han Sun; Wei-Ping Zhou
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 7.  Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

Authors:  Riccardo Lencioni; Xiao-Ping Chen; Lucy Dagher; Alan P Venook
Journal:  Oncologist       Date:  2010

8.  A positive feedback loop of long noncoding RNA CCAT2 and FOXM1 promotes hepatocellular carcinoma growth.

Authors:  Fei Chen; Guang Bai; Yuhong Li; Yanhong Feng; Liang Wang
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 9.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

10.  Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma.

Authors:  Haohai Zhang; Chengpei Zhu; Yi Zhao; Ming Li; Liangcai Wu; Xiaobo Yang; Xueshuai Wan; Anqiang Wang; Michael Q Zhang; Xinting Sang; Haitao Zhao
Journal:  Oncotarget       Date:  2015-12-22
View more
  1 in total

1.  Age-Related DNA Methylation in Normal Kidney Tissue Identifies Epigenetic Cancer Risk Susceptibility Loci in the ANKRD34B and ZIC1 Genes.

Authors:  Jürgen Serth; Inga Peters; Bastian Hill; Tatjana Hübscher; Jörg Hennenlotter; Michael Klintschar; Markus Antonius Kuczyk
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.